Acurable is a medical device business that has experienced accelerated growth in recent times. Their Series A fundraising round raised €11 million.
The medical device firm released the AcuPebble SA100 last year in Spain and the UK, generating huge success. The device makes it easier to identify and track OSA (obstructive sleep apnea) by allowing individuals to undergo entirely automated testing in their own homes. Acurable is currently seeking to increase its presence in the UK and Spain as well as diversify into other European and North American markets.
“Acurable's Series A fundraising round raised €11 million“
The AcuPebble SA100 is a trailblazer in the market, being the only electronic OSA device so far to have achieved the FDA 510(k) approval in America and the CE mark in Europe. Additionally, it is the only gadget that meets the US Agency for Healthcare Research and Quality's (AHRQ’s) standards for accurate value performance.
This financing comes after Nyxoah and AcuPebble declared a strategic distribution deal to bring the SA100 home sleep test to Germany.
Innovator and Inventor, Professor Esther Rodriguez-Villegas (Acurable's co-CEO) said that “this funding will help us reach our initial goal of diagnosing one million patients and gives us the opportunity to continue working on new products that will fundamentally improve the lives of millions of people living with severe chronic conditions.”
© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.See all the latest jobs in Medical Devices